母体血浆游离DNA检测指导复发性流产检查的经济影响
本研究基于既往验证数据(cfDNA检测复发性流产染色体异常灵敏度81.8%、特异度90.3%),构建决策分析模型比较三种复发性流产管理路径的成本。结果显示,cfDNA检测路径较现有流产组织细胞遗传学检测样本可及性更好、人均成本更低,且能增加致病性胎儿染色体异常的检出、减少不必要的检查,总体节约成本。
要点
- cfDNA检测指导复发性流产检查较流产组织细胞遗传学检测人均成本更低。
- cfDNA路径样本可及性更好,且增加致病性胎儿染色体异常检出。
- cfDNA路径减少不必要的复发性流产检查,总体节约成本。
核心结论
- 纳入cfDNA检测是指导复发性流产检查的一种成本有效的方法。
研究设计与样本
- 决策分析模型比较三种复发性流产管理路径:当前美国生殖医学学会(ASRM)复发性流产检查、流产组织微阵列或核型分析后仅对整倍体病例行复发性流产检查、cfDNA检测后仅对整倍体病例行复发性流产检查。
- 模型设定每种检测的样本可及性、失败率和灵敏度,并考虑样本采集、基因检测和复发性流产检查的成本。
- 分析结局包括染色体异常检出率和每例检测患者成本。
主要发现
- 与现有流产组织细胞遗传学检测相比,cfDNA检测路径样本可及性更好且每例患者成本更低。
- 使用cfDNA指导进一步检查显著增加检出的致病性胎儿染色体异常数量。
- cfDNA路径减少接受不必要检查的患者数量,从而总体节约成本。
关键数值与推荐
- 既往研究显示母体血浆cfDNA检测复发性流产染色体异常的灵敏度为81.8%、特异度为90.3%。
临床怎么用
- 在复发性流产检查路径中可考虑纳入母体血浆cfDNA检测以指导后续检查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We have previously demonstrated that maternal-plasma cell-free DNA (cfDNA)-testing can detect chromosomal anomalies in recurrent pregnancy loss (RPL) with 81.8% sensitivity and 90.3% specificity. Here we assess whether this is cost effective in guiding further workup in RPLs. METHOD: A decision-analytic model was developed to compare the cost of various RPL management pathways: (1) current American Society for Reproductive Medicine (ASRM) RPL workup; (2) microarray or karyotyping analysis of products of conception (POCs) and RPL workup only for euploid cases; and (3) cfDNA testing and RPL workup only for euploid cases. Sample accessibility, failure rates, and sensitivity were specified for each test. Costs of sample collection, genetic tests, and RPL workup were considered. Analysis outcomes included detection rate of chromosomal anomaly and cost per patient tested. RESULTS: In comparison to existing cytogenetic testing on POCs, cfDNA testing pathway allowed for better sample accessibility with a lower cost per patient. In addition, using cfDNA to guide further workup significantly increases the number of causative fetal chromosome anomalies detected, reducing the number of patients undergoing unnecessary workup resulting in an overall cost savings. CONCLUSION: Our study showed that inclusion of cfDNA testing is a cost-effective approach to guide RPL workup.
引用
- Peng S, Bhatt S, Borrell A, et al. Economic impact of using maternal plasma cell-free DNA testing to guide further workup in recurrent pregnancy loss. Prenat Diagn. 2021. PMID: 34002411. doi:10.1002/pd.5972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。